The 1000-Day CEO · Interview

Great technology does not become a great business on its own. The breakdown often occurs when founders must convert technical progress into investor confidence,

This episode of The 1000-Day CEO with Bill Canady is mirrored here for The 80/20 Institute audience. The canonical episode (full transcript + player) lives on 1000dayceo.com.

Transcript (extract)

Bill Canady: welcome back everyone. today most leaders assume that when growth stalls, the answer is more capital. But what if capital isn't the real constraint? What if the real problem is converting capital into capabilities, customers, and enterprise value? Today I'm joined by Heath Naquin, Senior Vice President of Innovation and New Ventures at the University City Science Center. we're going to explain why well-funded innovations fail to scale, where the conversion process breaks down, and how leaders can sequence capital against the milestones that create measurable value. Heath, welcome to the show.

Heath: Thanks, Bill, for having me.

Bill Canady: So most leaders believe, as we said in the intro, that gross stall is because of lab capital. You argue that capital is available. The real constraint is conversion. What does that mean? And where do leaders most often get it wrong?

Heath: And you know, in this environment, I mean, people be listening like, no, no, capital's super, super tight, and yeah, it is. Of course it is. But I think from my vantage point, and it depends on where you're at as a company, you know, capital usually isn't actually the problem. It's usually the structure

Bill Canady: Mm-hmm.

Heath: of the venture overall. You have a great tech and great plan and you're trying to raise capital. The issue when you keep getting told no, isn't usually, you know, the tech and it's not usually always the team. It's that the value prop hasn't been fully baked and the corporate hygiene isn't candidly there. Like you don't have any actually have that growth plan and that scale plan in a way that can be believed from capital markets. That's one slice of a part of the answer to your question. But an argument I would make for some of the CEOs, and something we talk about at the Science Center and in some of my other work, is there is an element of capital efficiency tied to corporate. Commercial milestones that often gets overlooked in doing that fundraise. And so the what I mean by that, so like in my in my day-to-day, I work with a lot of med tech and life science companies. Very capital-intensive, get those things from start to you know human launch. I mean, we're in the order of tens to fifties to hundreds of millions of dollars before it even sees light of day, right? But there's a lot of steps along the way. That if you were more capital efficient and designed things right from the get-go and you had a mind towards capital efficiency and say regulatory, knew when to spend money smartly, maybe cost you a little more upfront, but it saves you five million dollars. Hey, that's a good investment. And, you know, there's all kinds of stuff there. So I think that a lot of CEOs, at least the ones I run into in in my work, often are not thinking about the capital efficiency layer of how they're growing their company. And that does not mean being cheap. That means

Bill Canady: Mm-hmm.

Heath: being planful and thoughtful about your growth trajectory as it pertains to the capital stack and capital markets and the market itself. So that's slice two of my answer. Slice three, which gets back into where people most often get it wrong. And I think I I already brought up a couple of things that were wrong. But, you know, really. There a few more things that I mean, and granted, I see hundreds of companies a year. I I'm an active investor myself, so I see a lot of companies at all different stages. I think that a lot of CEOs as they're trying to grow and scale. Aren't necessarily thinking about growing and scaling in the right fashion towards a market reality. And it's real easy. I I I've been an operator role myself. It's I have made this mistake. So this is not trying to call anybody out. This is just it's real easy when you're in the middle of the of the scrum to to be have your blinders on like this is my mission, this is what I have to do, and lose sight a little bit of should you be growing that way or not? Is this the right team around me or not? Do I know enough to engage my experts in an appropriate way? To be capital efficient so that when I'm doing my fundraise and trying to find my capital, I'm asking for what I need related to value milestones and actually doing it in a way that's thoughtful and planful, which is real hard to do when you're on the treadmill twenty four seven. So those are just a few things and I feel like I went all over the place, Bill. I apologize, but hopefully there's some nuggets in there that were a little bit useful for the audience.

Bill Canady: That was a perfect answer and it really just speaks to the complexity of what's going on. But you really you really brought up a great point. What convinced you that this was the real problem when you're working with these guys, right? That that yeah,

Heath: the capital efficiency piece?

Bill Canady: the capital efficiency piece of it. Like what what was the it's a huge one.

Heath: so so quite honestly, this is like so again, I mentioned like MedTech Life Science, right? And it would I'd see companies and like and at the science center, we we routinely work with companies like this. So I'll do a shameless plug. I mean, we'll run 30 companies a year through our process, which is all it's all about capital readiness and raising your money, right? But you would see companies successfully raise funds, they would raise five, 10 million dollars. Great CEO, super happy, sweet, everything's going great. This is enough to get my regulatory pathway set. I can start doing my FDA approvals. then they can do my quality management system, design studies, and then some maybe some contract manufacturer stuff. And they start moving this money around for this plan that's all interrelated in some way. Right. So it's in I mean, if regulatory goes sideways, everything else changes, blah, blah, blah. So I started looking at that. And from what I can see, at least in MedTech. Two areas where people often get it wrong because they're at this earlier phase, they haven't raised money yet, whatever, is going cheap on regulatory, usually because they know a guy somewhere and they get some bad advice or maybe cheap advice. Not following the the regs, and so they they go cheap on their submissions. They have there's a timeline there while they're building out their their sort of manufacture strategy and going down the road, and then they find out eight months later. That, wait, FDA didn't approve it. You have to go back and…

Continue to the full episode and transcript →